MTA and 9.7% in the RFA group (p = 0.85). There was no mortality. Median hospital stay was 1 day for both groups. For the RFA vs MTA groups, local recurrence (LR) rate per lesion was 20.3% and 8.5%, respectively (p = 0.01). On Cox Proportion Hazards model, ablation modality was an independent predictor of LR following risk adjustment. Conclusion: To our knowledge, this is the first comparison of RFA and MTA in the treatment of CRLM. Our results demonstrates MTA achieves better local tumor control with shorter operative and ablation time.
Background: The survival impact of specific body composition changes (total weight, skeletal muscle mass, muscle density, and others) during preoperative chemotherapy in patients with resectable colorectal liver metastases (CRLM) remains unclear. Methods: Patients with CRLM who underwent preoperative chemotherapy and curative hepatectomy during 2009e 2013 were retrospectively analyzed using CT and automated muscle volume data (Fuji). Recurrence-free survival (RFS) and overall survival (OS) were examined according to muscle mass and -density and body weight before and after preoperative. Muscle mass was calculated by skeletal muscle index (SMI; area of muscle [cm 2 ]/square of height [m 2 ]). Results: The study included 169 patients, and the median follow-up period was 47 months. Neither SMI nor muscle density before or after preoperative chemotherapy was associated with RFS or OS. SMI and body weight changed significantly during chemotherapy (SMI: À0.52 cm 2 /m 2 , P = .03; median change in body weight: +1.1 kg, P = .002). Muscle mass change was not moderately or strongly correlated with body weight change, number of cycles of preoperative chemotherapy and chemo-resistance (assessed by tumor size, change of CEA, and pathological response). Patients with major muscle mass loss (!7%) had significantly shorter median RFS than patients with no/minor muscle mass loss (<7%) (9.6 months vs 15.9 months; P = .02). On multivariate analysis, major muscle mass loss was independently associated with poorer RFS (hazard ratio, 1.76; P = .045). Conclusion: Major loss of muscle mass but not body weight during preoperative chemotherapy is significantly associated with poor RFS after hepatectomy in patients with CRLM and, hence, should prompt consideration for prehabilitation. Background: The oncological benefit of complete metastasectomy for simultaneous colorectal liver and lung metastases (SLLM) and the significance of the time to surgical failure (TSF) in such patients are unknown. Methods: Patients undergoing hepatectomy from 2005 to 2016 as an initial treatment for colorectal liver metastases (CLM) in a single tertiary hospital were divided into three groups: patients with isolated CLM undergoing complete resection (Group 1, n = 317), SLLM undergoing complete metastasectomy (Group 2, n = 33), and SLLM undergoing complete hepatectomy but incomplete lung resection (Group 3, n = 20). Upfront surgery was performed for patients with initially resectable disease. A staged strategy (hepatectomy followed by lung resection) without interval chemotherapy was mainly applied for SLLM as long as the lung metastases were resectable. Clinical characteristics and prognoses were compared among the groups. Results: The 5-year overall survival rate of Group 2 was significantly better than that of Group 3 (70.3% vs. 11.9%, <.001) and similar to that of Group 1 (63.5%, "P" = .859). The 5-year disease-free survival rate was significantly worse in Group 2 than 1 (22.1% vs. 34.6%, =.048), while the 5-year TSF was similar (52.9% vs. 49.9%, =.991). On multivariable analysis, a carcinoembryonic antigen level of >200 ng/ml was the sole predictor of incomplete resection of lung metastases (odds ratio, 13.8; 95% confidence interval, 1.75e298; =.011). Conclusion: The prognosis in patients with SLLM who achieve complete metastasectomy is acceptable and might be improved by a carcinoembryonic antigen level of 200 ng/ml, appropriate selection based on operative indications, and aggressive repeat resection.
